A director proposes selling 1,209 Ligand Pharmaceuticals (LGND) shares around October 30, 2026.
Ligand Pharmaceuticals Inc. director Jason M. Aryeh has proposed selling 1,209 common shares of the company, valued at approximately $385,185.47, with an anticipated sale date of October 30, 2026. These shares are identified as restricted stock, which he acquired from Ligand Pharmaceuticals Inc. on June 5, 2026. The sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services.
Put this headline into context
Use TradingAgents AI to connect the story to the company's filings, fundamentals, market structure, competing bull and bear arguments, and risk review.
Headlines and excerpts belong to the original publisher. Ticker associations are informational and may be incomplete. Market news is not personalized financial advice.